Design Genetic Fluorescent Probes to Detect Protease Activity and Calcium-Dependent Protein-Protein Interactions in Living Cells
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Microrna-145 Overexpression Attenuates Apoptosis and Increases Matrix Synthesis in Nucleus Pulposus Cells T
Life Sciences 221 (2019) 274–283 Contents lists available at ScienceDirect Life Sciences journal homepage: www.elsevier.com/locate/lifescie MicroRNA-145 overexpression attenuates apoptosis and increases matrix synthesis in nucleus pulposus cells T Jie Zhoua,1, Jianchao Sunb,c,1, Dessislava Z. Markovad, Shuangxing Lib,c, Christopher K. Keplerd, ⁎ ⁎⁎ Junmin Hongb,c, Yingjie Huangb,e, Weijian Chene, Kang Xub,f, Fuxin Weig, , Wei Yeb,c, a Department of Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China b Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China c Department of Spine Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China d Department of Orthopaedic Surgery, Thomas Jefferson University, Philadelphia, USA e Department of Orthopedics, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China f Experimental Center of Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China g Department of Orthopedics, the Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China ARTICLE INFO ABSTRACT Keywords: Aims: Lower back pain is often associated with intervertebral disc degeneration (IDD), which results from a Intervertebral disc degeneration decrease in nucleus pulposus (NP) cells and an imbalance between the degradation and synthesis of extracellular Nucleus pulposus matrix (ECM) components. Multiple microRNAs play crucial roles in the modulation of NP cell apoptosis and microRNA-145 matrix degradation. miR-145 is an important microRNA related to degenerative diseases such as osteoarthritis. Apoptosis Here, the effect of miR-145 in IDD was elucidated. -
Repression of Anti-Proliferative Factor Tob1 in Osteoarthritic Cartilage
Available online http://arthritis-research.com/content/7/2/R274 ResearchVol 7 No 2 article Open Access Repression of anti-proliferative factor Tob1 in osteoarthritic cartilage Mathias Gebauer1*, Joachim Saas2*, Jochen Haag3, Uwe Dietz2, Masaharu Takigawa4, Eckart Bartnik2 and Thomas Aigner3 1Aventis Pharma Deutschland, Functional Genomics, Sanofi-Aventis, Frankfurt, Germany 2Sanofi-Aventis, Disease Group Thrombotic Diseases/Degenerative Joint Diseases, Frankfurt, Germany 3Osteoarticular and Arthritis Research, Department of Pathology, University of Erlangen-Nürnberg, Germany 4Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan * Contributed equally Corresponding author: Thomas Aigner, [email protected] Received: 10 Aug 2004 Revisions requested: 1 Oct 2004 Revisions received: 22 Oct 2004 Accepted: 19 Nov 2004 Published: 11 Jan 2005 Arthritis Res Ther 2005, 7:R274-R284 (DOI 10.1186/ar1479)http://arthritis-research.com/content/7/2/R274 © 2005 Gebauer et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Osteoarthritis is the most common degenerative disorder of the genes were detected between normal and osteoarthritic modern world. However, many basic cellular features and cartilage (P < 0.01). One of the significantly repressed genes, molecular processes of the disease are poorly understood. In Tob1, encodes a protein belonging to a family involved in the present study we used oligonucleotide-based microarray silencing cells in terms of proliferation and functional activity. -
Pronase Kit Pretreatment Reagent 901-PRT957-081017
Carezyme III: Pronase Kit Pretreatment Reagent 901-PRT957-081017 Catalog Number: PRT957 KH Description: 25 ml, ready-to-use Intended Use: stored under conditions other than those specified in the package For In Vitro Diagnostic Use insert, they must be verified by the user. Diluted reagents should be Carezyme III: Pronase Kit is a concentrated solution of pronase used promptly; any remaining reagent should be stored at 2ºC to 8ºC. enzyme and accompanying buffer intended for use as a pretreatment Troubleshooting: step on formalin-fixed, paraffin-embedded (FFPE) tissues in Follow the antibody specific protocol recommendations according to immunohistochemistry (IHC) and in situ hybridization (ISH) data sheet provided. If atypical results occur, contact Biocare's procedures. The clinical interpretation of any staining or its absence Technical Support at 1-800-542-2002. should be complemented by morphological studies and proper controls Protocol Recommendations: and should be evaluated within the context of the patient's clinical Deparaffinize tissues and hydrate to water. If necessary perform a history and other diagnostic tests by a qualified pathologist. hydrogen peroxide block, wash in water, and rinse in PBS or TBS. The Summary and Explanation: tissue section is ready for protease digestion. Pronase (Streptomyces griseus) is a commonly used digestive enzyme. Manual IHC: In formalinfixed paraffin-embedded tissues, certain antibody or in situ 1. Combine 1 part Pronase concentrate with 4 parts buffer (0.1%). hybridization probes require enzyme pretreatment for proper Incubate for 5-10 minutes at 37ºC. (Strong) immunohistochemical or in situ hybridization staining. CAREZYME III is 2. Combine 1 part Pronase concentrate with 9 parts buffer (0.05%). -
WO2021044381A1.Pdf
( (51) International Patent Classification: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, G01N 33/543 (2006.01) COIN 21/00 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, (21) International Application Number: SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, PCT/IB2020/058284 TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 04 September 2020 (04.09.2020) kind of regional protection available) . ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (26) Publication Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (30) Priority Data: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/897,042 06 September 2019 (06.09.2019) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, (72) Inventors; and KM, ML, MR, NE, SN, TD, TG). (71) Applicants: GORI, Alessandro [IT/IT]; Via Murri 23, 20871 Vimercate (IT). CRETICH, Marina [IT/IT]; Via Published: Zurigo 20, 20147 Milano (IT). CHIARI, Marcella [IT/IT]; — with international search report (Art. 21(3)) Via Gian Battista Brochi 11, 2013 1 Milano (IT). -
Mediates Neuronal Abeta42 Uptake and Lysosomal Trafficking Rodrigo A
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2010 Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking Rodrigo A. Fuentealba Washington University School of Medicine in St. Louis Qiang Liu Washington University School of Medicine in St. Louis Juan Zhang Washington University School of Medicine in St. Louis Takahisa Kanekiyo Washington University School of Medicine in St. Louis Xiaoyan Hu Washington University School of Medicine in St. Louis See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Part of the Medicine and Health Sciences Commons Recommended Citation Fuentealba, Rodrigo A.; Liu, Qiang; Zhang, Juan; Kanekiyo, Takahisa; Hu, Xiaoyan; Lee, Jin-Moo; LaDu, Mary Jo; and Bu, Guojun, ,"Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking." PLoS One.,. e11884. (2010). https://digitalcommons.wustl.edu/open_access_pubs/698 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Rodrigo A. Fuentealba, Qiang Liu, Juan Zhang, Takahisa Kanekiyo, Xiaoyan Hu, Jin-Moo Lee, Mary Jo LaDu, and Guojun Bu This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/698 Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Mediates Neuronal Ab42 Uptake and Lysosomal Trafficking Rodrigo A. Fuentealba1,2., Qiang Liu1., Juan Zhang1, Takahisa Kanekiyo1, Xiaoyan Hu2, Jin-Moo Lee2, Mary Jo LaDu3, Guojun Bu1,4* 1 Department of Pediatrics, Washington University School of Medicine, St. -
Serine Proteases with Altered Sensitivity to Activity-Modulating
(19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants. -
Proteolytic Enzymes
Proteolytic Enzymes Proteolytic Stock Storage Concentration Reaction Enzyme Solution Temperature in Reaction Buffer Temperature Pretreatment 1 2 Pronase 20mg/mL in H2O –20°C 1mg/mL 0.01M Tris 37°C Self-digestion (pH 7.8) 0.01M EDTA 0.5% SDS 3 Proteinase K 20mg/mL in H2O –20°C 50µg/mL 0.01M Tris 37° to 56°C None required (pH 7.8) 0.005M EDTA 0.5% SDS 1 Pronase is a mixture of serine and acid proteases isolated from Streptomyces griseus. 2 Self-digestion eliminates contamination with DNase and RNase. Self-digested Pronase is prepared by dissolving powdered Pronase in 10mM Tris•Cl (pH 7.5), 10mM NaCl to a final concentration of 20mg/mL and incubating for 1 hour at 37°C. Store the self-digested Pronase in small aliquots at –20°C in tightly capped tubes. 3 Proteinase K is a highly active protease of the subtilisin type that is purified from the mould Tritirachium album Limber. The enzyme has two binding sites for Ca2+, which lie some distance from the active site and are not directly involved in the catalytic mechanism. However, when Ca2+ is removed from the enzyme, approxi- mately 80% of the catalytic activity is lost because of long-range structural changes (Bajorath et al. Nature 1989; 337:481-484). Because the residual activity is usually sufficient to degrade proteins that commonly contaminate preparations of nucleic acids, digestion with Proteinase K is usually carried out in the presence of EDTA (to inhibit the action of Mg2+-dependent nucleases). However, to digest highly resistant proteins such as keratin, it may be necessary to use a buffer con- taining 1mM Ca2+ and no EDTA. -
Complete Amino Acid Sequence of Human Plasma Zn-A2-Glycoprotein and Its Homology to Histocompatibility Antigens
Proc. Nati. Acad. Sci. USA Vol. 85, pp. 679-683, February 1988 Biochemistry Complete amino acid sequence of human plasma Zn-a2-glycoprotein and its homology to histocompatibility antigens (plasma protein structure/glycan structure//HLA dass I antigens/secretory major histocompatibility complex-related protein/immnnoglobuiln gene superfamily) TOMOHIRO ARAKI*, FUMITAKE GEJYO*t, KEIICHI TAKAGAKI*, HEINZ HAUPT*, H. GERHARD SCHWICKt, WILLY BURGI§, THOMAS MARTI¶, JOHANN SCHALLER¶, EGON RICKLI¶, REINHARD BROSSMER11, PAUL H. ATKINSON**, FRANK W. PUTNAMtt, AND KARL SCHMID*# *Department of Biochemistry, Boston University School of Medicine, Boston University Medical Center, Boston, MA 02118; *Behringwerke AG, 3550 Marburg/Lahn, Federal Republic of Germany; lZentrallaboratorium, Kantonsspital, 5001 Aarau, and lInstitut fOr Biochemie, University of Berne, 3012 Berne, Switzerland; IlDepartment of Biochemistry, University of Heidelberg Medical School, 6900 Heidelberg, Federal Republic of Germany; **Department of Developmental Biology and Cancer, Albert Einstein College of Medicine, Bronx, NY 10461; and ttDepartment of Biology, Indiana University, Bloomington, IN 47405 Contributed by Frank W. Putnam, September 22, 1987 ABSTRACT In the present study the complete amino acid like determinant in common with nephritogenic urinary sequence of human plasma Zn-a2-glycoprotein was deter- glycoproteins (2, 4). mined. This protein whose biological function is unknown In this paper we describe the determination of the com- consists of a single polypeptide chain of 276 amino acid plete amino acid sequence of Zna2gp, including the location residues including 8 tryptophan residues and has a pyroglu- of the two disulfide bridges and the structure of the three tamyl residue at the amino terminus. The location of the two carbohydrate units, and we discuss the possible secondary disuhlde bonds in the polypeptide chain was also established. -
A Broad-Spectrum Humanlung Fibroblast-Derived Mitogen Is A
Proc. Natl. Acad. Sci. USA Vol. 88, pp. 415-419, January 1991 Biochemistry A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor (heparin-binding growth factor/plasminogen/epithelial cells/endothelial ceils/melanocytes) JEFFREY S. RUBIN*, ANDREW M.-L. CHAN*, DONALD P. BOTTARO*, WILSON H. BURGESSt, WILLIAM G. TAYLOR*, ALEX C. CECH*, DAVID W. HIRSCHFIELD*, JANE WONG*, TORU MIKI*, PAUL W. FINCH*t, AND STUART A. AARONSON*§ *Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, MD 20892; and tLaboratory of Molecular Biology, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross, Rockville, MD 20855 Communicated by William H. Daughaday, October 10, 1990 (receivedfor review July 12, 1990) ABSTRACT A heparin-binding mitogen was isolated from Mitogenic Assays. DNA synthesis in the B5/589, BALB/ conditioned medium of human embryonic king fibroblasts. It MK, CCL208, and NIH 3T3 lines (10) and in primary exhibited broad target-cell specificity whose pattern was dis- melanocytes (11) was measured as described elsewhere. For tinct from that of any known growth factor. It rapidly stimu- proliferation assays (12), HUVECs were plated at 4 X 104 lated tyrosine phosphorylation of a 145-kDa protein in respon- cells per 6-cm tissue culture dish in basal medium (in the sive cells, suggesting that its signaling pathways involved presence or absence of heparin) supplemented with recom- activation of a tyrosine kinase. Purification identified a major binant aFGF or basic FGF (bFGF) (10 ng/ml) or HSAC- polypeptide with an apparent molecular mass of 87 kDa under purified, fibroblast-derived growth factor (-'100 ng/ml). -
LCMS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis
C146-E340 LCMS Bioanalysis of Antibody Drugs Using Technical Fab-selective Proteolysis “nSMOL Method” Report — Selection of Signature Peptide — Noriko Iwamoto1, Takashi Shimada1 Abstract: nSMOL (nano-surface and molecular-orientation limited proteolysis) is Shimadzu's completely new, proprietary, and innovative technique for selective proteolysis of Fab region of monoclonal antibodies. nSMOL allows analytical method development of antibody drugs indepen- dent of a variety of antibody drugs. Fab-derived peptide fragments produced by nSMOL can be precisely quantified by multiple reaction monitoring (MRM) using the Shimadzu LCMS-8050/8060 triple quadrupole liquid chromatograph mass spectrometer (TQ-LCMS). This report describes a selection protocol of signature peptides suitable for pharmacokinetic studies. Keywords: nano-surface and molecular-orientation limited proteolysis, antibody drug, bioanalysis, LC/MS/MS 1. Introduction A peptide for quantitation (signature peptide) is selected from the tryptic peptides containing a complementarity-determining region Pharmacokinetic information provides some of the most fundamental (CDR), which defines the specificity of the antibody. However, it is not indicators. The effective drug discovery is supported by the overall possible that the CDR-containing peptide does not have the same pharmacokinetic profile such as for drug efficacy and toxicity. amino acid sequence as that in the endogenous IgGs. At this point, it must be confirmed that there is no competition with the signature The current method used for measuring drug concentration in blood peptide in the biological matrix. is enzyme-linked immunosorbent assay (ELISA). However, there are critical issues with ELISA, including influences from cross-reaction and inhibitory materials. In contrast, by MS, analysis is performed based on the structural information; thus, the aforementioned issues can 2. -
Fluorescent Probes for Nucleic Acid Visualization in Fixed and Live Cells
Molecules 2013, 18, 15357-15397; doi:10.3390/molecules181215357 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Fluorescent Probes for Nucleic Acid Visualization in Fixed and Live Cells Alexandre S. Boutorine 1,*, Darya S. Novopashina 2, Olga A. Krasheninina 2,3, Karine Nozeret 1 and Alya G. Venyaminova 2 1 Muséum National d’Histoire Naturelle, CNRS, UMR 7196, INSERM, U565, 57 rue Cuvier, B.P. 26, Paris Cedex 05, F-75231, France; E-Mail: [email protected] 2 Institute of Chemical Biology and Fundamental Medicine, Siberian Division of Russian Academy of Sciences, Lavrentyev Ave., 8, Novosibirsk 630090, Russia; E-Mails: [email protected] (D.S.N.); [email protected] (O.A.K.); [email protected] (A.G.V.) 3 Department of Natural Sciences, Novosibirsk State University, Pirogova Str., 2, Novosibirsk 630090, Russia * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +33-1-40-79-36-96; Fax: +33-1-40-79-37-05. Received: 23 September 2013; in revised form: 20 November 2013 / Accepted: 5 December 2013 / Published: 11 December 2013 Abstract: This review analyses the literature concerning non-fluorescent and fluorescent probes for nucleic acid imaging in fixed and living cells from the point of view of their suitability for imaging intracellular native RNA and DNA. Attention is mainly paid to fluorescent probes for fluorescence microscopy imaging. Requirements for the target-binding part and the fluorophore making up the probe are formulated. In the case of native double-stranded DNA, structure-specific and sequence-specific probes are discussed. -
(12) Patent Application Publication (10) Pub. No.: US 2009/0192073 A1 HABERMANN Et Al
US 20090192073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0192073 A1 HABERMANN et al. (43) Pub. Date: Jul. 30, 2009 (54) METHOD FOR PRODUCING INSULIN (30) Foreign Application Priority Data ANALOGS HAVINGADBASICB CHAN TERMINUS Jul. 11, 2006 (DE) ......................... 102OO6031955.9 (75) Inventors: to thisETErt an Publication Classification Frankfurt am Main (DE) (51) Int. Cl. A638/28 (2006.01) Correspondence Address: CI2P 2L/06 (2006.01) ANDREA Q. RYAN C07K I4/62 (2006.01) SANOF-AVENTIS U.S. LLC 104.1 ROUTE 202-206, MAIL CODE: D303A BRIDGEWATER, NJ 08807 (US) (52) U.S. Cl. ............................. 514/3; 435/68.1:530/303 (73) Assignee: SANOF-AVENTS DEUTSCHLAND GMBH, Frankfurtr am Main (DE)(DE (57) ABSTRACT (21) Appl. No.: 12/349,854 1-1. The invention relates to a method for producing a type of (22) Filed: Jan. 7, 2009 insulin by genetically engineering a precursor thereof and Related U.S. Application Data converting said precursor to the respective insulin in an .S. App enzyme-catalyzed ligation reaction with lysine amide or argi (63) Continuation of application No. PCT/EP2007/ nine amide, or by lysine or arginine which is modified by 005933, filed on Jul. 5, 2007. protective groups, and optionally Subsequent hydrolysis. US 2009/0192073 A1 Jul. 30, 2009 METHOD FOR PRODUCING INSULIN acids and the B chain with 30 amino acids. The chains are ANALOGS HAVING ADIBASIC B CHAIN linked together by 2 disulfide bridges. Insulin preparations TERMINUS have been employed for many years for the therapy of diabe tes. Moreover, not only are naturally occurring insulins used, but more recently also insulin derivatives and analogs.